Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cerilliant
Citi
Mallinckrodt
Baxter
UBS
Boehringer Ingelheim
Fuji
AstraZeneca
US Department of Justice

Generated: May 26, 2018

DrugPatentWatch Database Preview

Tentative Approvals for: Aurobindo Pharma Usa

« Back to Dashboard

Aurobindo Pharma Usa Drugs with Tentative Approvals

Applicant Generic Name NDA Strength Dosage Form
Aurobindo Pharma Usa atomoxetine hydrochloride 079016 40MG CAPSULE; ORAL
Aurobindo Pharma Usa efavirenz 205322 600MG TABLET;ORAL
Aurobindo Pharma Usa pregabalin 205321 100MG CAPSULE;ORAL
Aurobindo Pharma Usa atomoxetine hydrochloride 079016 60MG CAPSULE; ORAL
Applicant Generic Name NDA Strength Dosage Form

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Medtronic
Cantor Fitzgerald
Argus Health
UBS
Colorcon
Queensland Health
Moodys
Baxter
Federal Trade Commission

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.